Loading...

FITC anti-mouse CD4 Antibody

Pricing & Availability
Clone
GK1.5 (See other available formats)
Regulatory Status
RUO
Other Names
L3T4, T4
Isotype
Rat IgG2b, κ
Ave. Rating
Submit a Review
Product Citations
publications
GK1.5_FITC_102110
C57BL/6 mouse splenocytes were stained with CD4 (clone GK1.5) FITC (filled histogram) or rat IgG2b, κ FITC isotype control (open histogram).
  • GK1.5_FITC_102110
    C57BL/6 mouse splenocytes were stained with CD4 (clone GK1.5) FITC (filled histogram) or rat IgG2b, κ FITC isotype control (open histogram).
Compare all formats See FITC spectral data
Cat # Size Price Quantity Check Availability Save
100405 50 µg 24€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
100406 500 µg 80€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD4 is a 55 kD protein also known as L3T4 or T4. It is a member of the Ig superfamily, primarily expressed on most thymocytes, a subset of T cells, and weakly on macrophages and dendritic cells. It acts as a coreceptor with the TCR during T cell activation and thymic differentiation by binding MHC class II and associating with the protein tyrosin kinase, lck.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Mouse CTL clone V4
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with FITC under optimal conditions.
Concentration
0.5 mg/ml
Storage & Handling
The CD4 antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.25 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Application Notes

Additional reported applications (for the relevant formats) include: blocking of CD4+ T cell activation1,4,11, thymocyte costimulation3, in vitro and in vivo depletion2,5-8, blocking of egg-sperm cell adhesion1,4, immunohistochemical staining of acetone-fixed frozen sections9,10, immunoprecipitation1,2, and spatial biology (IBEX)12,13. The GK1.5 antibody is able to block CD4 mediated cell adhesion and T cell activation. Binding of GK1.5 antibody to CD4 T cells can be blocked by RM4-5 antibody, but not RM4-4 antibody. For in vivo studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 100442) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin < 0.01 EU/µg).

Application References
  1. Dialynas DP, et al. 1983. J. Immunol. 131:2445. (Block, IP)
  2. Dialynas DP, et al. 1983. Immunol. Rev. 74:29. (IP, Deplete)
  3. Wu L, et al. 1991. J. Exp. Med. 174:1617. (Costim)
  4. Godfrey DI, et al. 1994. J. Immunol. 152:4783. (Block)
  5. Gavett SH, et al. 1994. Am. J. Respir. Cell. Mol. Biol. 10:587. (Deplete)
  6. Schuyler M, et al. 1994. Am. J. Respir. Crit. Care Med. 149:1286. (Deplete)
  7. Ghobrial RR, et al. 1989. Clin. Immunol. Immunopathol. 52:486. (Deplete)
  8. Israelski DM, et al. 1989. J. Immunol. 142:954. (Deplete)
  9. Zheng B, et al. 1996. J. Exp. Med. 184:1083. (IHC)
  10. Frei K, et al. 1997. J. Exp. Med. 185:2177. (IHC)
  11. Felix NJ, et al. 2007. Nat. Immunol. 8:388. (Block)
  12. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  13. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Djokić V, et al. 2019. Front Immunol. 9:2891. PubMed
  2. Katsumura KR, et al. 2018. Proc Natl Acad Sci U S A. 115:E10109. PubMed
  3. Valanparambil RM, et al. 2017. PLoS Pathog. 13:e1006647. PubMed
  4. Wang X, et al. 2019. Cell Res. 29:787. PubMed
  5. Zhao J, et al. 2021. Emerg Microbes Infect. 10:913. PubMed
  6. Liu J, et al. 2021. Front Immunol. 12:747730. PubMed
  7. Su Y, et al. 2022. J Hematol Oncol. 15:99. PubMed
  8. Li Z, et al. 2022. Nat Commun. 13:1845. PubMed
  9. Zelenka T, et al. 2022. Nat Commun. 13:6954. PubMed
  10. Chuang H, et al. 2014. Nat Commun. 5:4602. PubMed
  11. Chang YS, et al. 2020. Int J Mol Sci. 21:00. PubMed
  12. Wu N, et al. 2020. Cell Rep. 30:1129. PubMed
  13. Alissafi T, et al. 2018. J Clin Invest. 128:3840. PubMed
  14. Yang Z, et al. 2022. J Immunother Cancer. 10:. PubMed
  15. Li Q, et al. 2022. Cell Rep. 40:111308. PubMed
  16. Schönberger K, et al. 2022. Cell Stem Cell. 29:131. PubMed
  17. He R, et al. 2021. J Immunol. 206:2353. PubMed
  18. Ma J, et al. 2020. Adv Sci (Weinh). 7:2000609. PubMed
  19. Fan L, et al. 2021. Cancers (Basel). 13:. PubMed
  20. Rosenkranz SC, et al. 2021. eLife. 10:00. PubMed
  21. Furuta Y, et al. 2017. PLoS One. 12(2):e0172509. PubMed
  22. Saleh MM, et al. 2019. Cell Host Microbe. 25:756. PubMed
  23. Yang F, et al. 2021. Front Microbiol. 11:512581. PubMed
  24. Luo R, et al. 2021. Theranostics. 11:117. PubMed
  25. Xu ZH, et al. 2021. Mediators Inflamm. 2021:8856326. PubMed
  26. Liang S, et al. 2022. Acta Pharm Sin B. 12:2494. PubMed
  27. Jiang W, et al. 2022. Front Immunol. 13:878832. PubMed
  28. Toomer G, et al. 2022. Viruses. 14:. PubMed
  29. Sega E, et al. 2008. Int J Radiat Oncol Biol Phys. 71:559. PubMed
  30. Lua Y, et al. 2012. Mol Immunol. 52:229. PubMed
  31. Zasłona Z, et al. 2014. J Immunol. 193:4245. PubMed
  32. Aguilera T, et al. 2016. Nat Commun. 7:13898. PubMed
  33. Periasamy S, et al. 2017. Nat Commun. 8:15564. PubMed
  34. Pobezinskaya EL et al. 2019. Front Immunol. 1.079861111 . PubMed
  35. Choi H et al. 2019. Cell Rep. 27(3):806-819 . PubMed
  36. Liang Q, et al. 2022. iScience. 25:104043. PubMed
  37. Mirshahi F, et al. 2022. Cell Rep. 38:110454. PubMed
  38. Bangs DJ, et al. 2022. Cell Rep. 38:110266. PubMed
  39. Jazowiecka-Rakus J, et al. 2021. Cancers (Basel). 13:. PubMed
  40. Chen J, et al. 2022. J Nanobiotechnology. 20:283. PubMed
  41. Wu M, et al. 2021. Nat Commun. 12:3500. PubMed
  42. Fu Y, et al. 2020. Mol Ther. 1214:28. PubMed
  43. Altshuler A, et al. 2021. Cell Stem Cell. 28(7):1248-1261.e8. PubMed
  44. Tang Y, et al. 2020. Front Immunol. 11:585918. PubMed
  45. Qi X, et al. 2019. Nat Commun. 10:2141. PubMed
  46. Wu J, et al. 2020. Sci Adv. 6:eaba3458. PubMed
  47. Aqel SI, et al. 2021. JCI Insight. 6:e142376. PubMed
  48. Hu D, et al. 2021. J Cell Mol Med. 25:2900. PubMed
  49. Shi S, et al. 2020. Clin Cancer Res. 26:5990. PubMed
  50. Wang Y, et al. 2022. Acta Pharm Sin B. 12:262. PubMed
  51. Zhou HF, et al. 2022. Front Pharmacol. 13:778755. PubMed
  52. Liang Z, et al. 2021. J Cell Physiol. 236:4725. PubMed
  53. Mardomi A, et al. 2021. J Cell Physiol. 236:6328. PubMed
  54. Xu F, et al. 2022. Cell Death Discov. 8:142. PubMed
  55. Guan H, et al. 2012. PLoS One. 7:e35650. PubMed
  56. D Kim, S Lee, H Jun 2016. Immunol Cell Biol. 10.1038/icb.2016.98. PubMed
  57. He C, et al. 2020. Clin Transl Med. 10:e39. PubMed
  58. Molina-Sanchez P, et al. 2020. Gastroenterology. 2203:159. PubMed
  59. Sarapulov AV, et al. 2020. Front Immunol. 11:599. PubMed
  60. Thomas S, et al. 2019. J Immunother Cancer. 7:214. PubMed
  61. Tritama E, et al. 2018. Hum Vaccin Immunother. 14:1524. PubMed
  62. Mauduit O, et al. 2022. Front Immunol. 13:1011125. PubMed
  63. Liu Y, et al. 2022. Nat Commun. 13:2665. PubMed
  64. Anastasiou M, et al. 2021. JCI Insight. 6:. PubMed
  65. Li H, et al. 2021. Nat Commun. 12:2773. PubMed
  66. Jiang S, et al. 2020. Scand J Immunol. e12867:91. PubMed
  67. Mitchell JE, et al. 2021. Cell Reports. 35(2):108966. PubMed
  68. White C, et al. 2014. J Immunol. 193:5933. PubMed
  69. Zongyi Y, et al. 2017. PLoS One. 10.1371/journal.pone.0189617. PubMed
  70. Cheng K, et al. 2021. Nat Commun. 12:2041. PubMed
  71. Edwards CJ, et al. 2021. Br J Cancer. . PubMed
  72. Jing L, et al. 2022. Front Immunol. 13:864995. PubMed
  73. Feng H, et al. 2020. J Dermatol. 47:147. PubMed
  74. Ren HZ, et al. 2022. J Clin Transl Hepatol. 10:1138. PubMed
  75. Ma X, et al. 2021. Cell Metabolism. 33(5):1001-1012.e5. PubMed
  76. Pedraza–Zamora CP, et al. 2017. Parasite Immunol. 39:4. PubMed
  77. Raineri D, et al. 2021. Biomedicines. 10:. PubMed
  78. He X, et al. 2021. Small. 17:e2007165. PubMed
  79. Katsinas N, et al. 2022. J Clin Med. 11:. PubMed
  80. He X, et al. 2021. Adv Sci (Weinh). 8:e2103023. PubMed
  81. Chen L, et al. 2021. Cell Death Differ. 28:1880. PubMed
  82. Wang Z, et al. 2020. J Clin Invest. 130:3717. PubMed
  83. Zhang W, et al. 2019. Oncol Lett. 17:815. PubMed
  84. Cervera–Carrascon V, et al. 2020. Oncoimmunology. 9:1761229. PubMed
  85. Paul S, et al. 2018. Appl Microbiol Biotechnol. 102:8895. PubMed
  86. Cheng B, et al. 2022. Cancer Commun (Lond). 42:17. PubMed
  87. Wang Z, et al. 2022. Nat Biomed Eng. 6:791. PubMed
  88. Guo P, et al. 2021. J Immunol. 207:408. PubMed
  89. Vigeland C, et al. 2016. PLoS One. 11: 0163288. PubMed
  90. Lu X, et al. 2016. Nat Commun. 7: 12719. PubMed
  91. Deng Z, et al. 2020. World J Gastrointest Oncol. 1091:12. PubMed
  92. Dmitrieva‐Posocco O et al. 2019. Immunity. 50(1):166-180 . PubMed
  93. Kim JH, et al. 2019. Mol Med. 25:33. PubMed
  94. Niknam S, et al. 2018. Clin Cancer Res. 24:5735. PubMed
  95. Habib S, et al. 2018. Infect Immun. 86:e00019. PubMed
  96. Zhao X, et al. 2022. Nat Protoc. 17:2240. PubMed
  97. Zhou H, et al. 2022. Oncoimmunology. 11:2057892. PubMed
  98. He X, et al. 2022. Cancer Immunol Res. 10:314. PubMed
  99. Hum NR, et al. 2022. Front Oncol. 12:928474. PubMed
  100. Zeng Q, et al. 2022. Front Immunol. 13:740805. PubMed
  101. Zuo S, et al. 2021. J Immunother Cancer. 9:. PubMed
  102. Zhang Y, et al. 2021. J Immunol Res. 2021:5599439. PubMed
  103. Volberding PJ, et al. 2021. Cell Reports. 35(8):109160. PubMed
  104. Knocke S, et al. 2016. Cell Rep. 17:2234-2246. PubMed
  105. Ahmari N, et al. 2016. Physiol Genomics. 48: 526 - 536. PubMed
  106. Ito C, et al. 2015. PLoS One. 10: e0140808. PubMed
  107. Zhang H, et al. 2019. Mol Cell. 76:110. PubMed
  108. Haas MS, et al. 2020. Mol Cancer Res. 19:717. PubMed
  109. Zhu Y, et al. 2021. EMBO J. 40:e105320. PubMed
  110. Wang Y, et al. 2021. Front Microbiol. 12:701566. PubMed
  111. Gebre MS, et al. 2022. NPJ Vaccines. 7:88. PubMed
  112. Yang B, et al. 2022. Bioengineered. 13:2685. PubMed
  113. Uddback I, et al. 2016. Sci Rep. 6:20137. PubMed
  114. Toomer K, et al. 2016. J Immunol. 196: 3665 - 3676. PubMed
  115. Faust HJ, et al. 2020. J Clin Invest. 130:5493. PubMed
  116. Kruta M, et al. 2021. Cell Stem Cell. :. PubMed
  117. Zhou J, et al. 2019. Nat Commun. 10:2427. PubMed
  118. Sun H, et al. 2022. Front Immunol. 13:818017. PubMed
  119. Frost JN, et al. 2021. Med (N Y). 2:164. PubMed
  120. Ding P, et al. 2022. Bone Res. 10:42. PubMed
  121. Lang V, et al. 2021. Elife. 10:. PubMed
  122. Peng L, et al. 2022. Cell Rep Med. 3:100634. PubMed
  123. Huang L, et al. 2021. Breast Cancer Res Treat. Online ahead of print. PubMed
  124. Lu J, et al. 2021. Cell Death Discov. 7:165. PubMed
  125. Han F, et al. 2020. Invest Ophthalmol Vis Sci. 61:24. PubMed
  126. Yan J, et al. 2020. Cell Rep. 107820:31. PubMed
  127. Shannon JP, et al. 2021. Immunity. 54(2):276-290.e5. PubMed
  128. Mencl S, et al. 2014. J Neuroimmunol. 274:125. PubMed
  129. Subramanian K, et al. 2019. Nat Microbiol. 4:62. PubMed
  130. Yang BH, et al. 2020. Cell Reports. 27(12):3629-3645.e6.. PubMed
  131. Tao Z, et al. 2019. Clin Cancer Res. 25:1113. PubMed
  132. Zhang Q, et al. 2021. Front Cell Dev Biol. 9:655552. PubMed
  133. Guo S, et al. 2021. Sci Rep. 11:23745. PubMed
  134. Ma K, et al. 2022. iScience. 25:104347. PubMed
  135. Li J, et al. 2022. Nat Commun. 13:4032. PubMed
  136. Gao X, et al. 2022. Front Immunol. 13:799331. PubMed
  137. Zeng Q, et al. 2022. iScience. 25:105151. PubMed
  138. Kmieciak M, et al. 2011. J Vis Exp. 47: 2381. PubMed
  139. Li Y, Kaneda T 2016. Sci Rep. 6: 25077. PubMed
  140. Timilshina M, et al. 2017. PLoS One. 10.1371/journal.pone.0168942. PubMed
  141. Wang X, et al. 2020. Nat Commun. 4.505555556. PubMed
  142. Wei Z, et al. 2021. Nat Commun. 0.805555556. PubMed
  143. Kamata T, et al. 2020. Cell Reports. 31(12):107802. PubMed
  144. Ouyang S, et al. 2019. J Immunol. 202:1441. PubMed
  145. Reynolds CJ, et al. 2018. Sci Rep. 8:672. PubMed
  146. Li Z, et al. 2022. Nat Commun. 13:6321. PubMed
  147. He C, et al. 2022. Nat Commun. 13:5459. PubMed
  148. Takaku S, et al. 2022. Evid Based Complement Alternat Med. 2022:6122955. PubMed
  149. Zhang S, et al. 2022. Nat Commun. 13:4744. PubMed
  150. Yuan M, et al. 2022. Oxid Med Cell Longev. 2022:5479491. PubMed
  151. Li J, et al. 2020. Development. . PubMed
  152. Shibuya M, et al. 2021. iScience. 24:103131. PubMed
  153. Nasarre P, et al. 2021. Cancers (Basel). 13: . PubMed
  154. Wang Y, et al. 2020. Virol Sin. 36:122. PubMed
  155. Liu Y, et al. 2020. Oncol Lett. 2369:20. PubMed
  156. Martomo SA, et al. 2021. Mol Cancer Ther. 1.074305556. PubMed
  157. Zan H, et al. 2017. Nat Commun. 8:14244. PubMed
  158. Nechama M, et al. 2018. Nat Commun. 9:1603. PubMed
  159. Xia Y, et al. 2018. Cell. 175:1059. PubMed
  160. Liu YG, et al. 2019. FASEB J. 33:5018. PubMed
  161. Yao C, et al. 2018. Autophagy. 1.854861111. PubMed
  162. Zhang Q, et al. 2022. Commun Biol. 5:544. PubMed
  163. Jazowiecka-Rakus J, et al. 2020. Mol Ther Oncolytics. 18:335. PubMed
  164. Soria-Castro R, et al. 2020. Sci Rep. 10:17802. PubMed
  165. Chen H, et al. 2022. Front Pharmacol. 13:827520. PubMed
  166. Karanika S, et al. 2022. Front Immunol. 13:972266. PubMed
  167. Ligon MM, et al. 2020. Mucosal Immunol. 1.172222222. PubMed
  168. Da Mesquita S, et al. 2021. Science Advances. 7(21):. PubMed
  169. Wedekind MF, et al. 2021. iScience. 24(7):102759. PubMed
  170. Khosravi N, et al. 2018. Cancer Immunol Res. 0.797222222. PubMed
  171. Kos S, et al. 2019. PLoS One. 14:e0217762. PubMed
  172. Ji L et al. 2019. Immunity. 51(2):272-284 . PubMed
  173. Habtetsion T et al. 2018. Cell metabolism. 28(2):228-242 . PubMed
  174. Coley WD et al. 2018. F1000Research. 2018 Mar 14 [revised 2018 Jan 1] 0.5125. PubMed
  175. Pan L, et al. 2022. Front Immunol. 13:837497. PubMed
  176. Zheng Y, et al. 2022. J Immunol. 208:501. PubMed
  177. He X, et al. 2021. J Immunother Cancer. 9:. PubMed
  178. Zhou H, et al. 2021. Cell Death Discov. 7:332. PubMed
  179. Liu Y, et al. 2020. Cell Death Dis. 11:1062. PubMed
  180. Si J, et al. 2020. Cancer Cell. 38(4):551-566.e11. PubMed
  181. Golan K et al. 2018. Cell stem cell. 23(4):572-585 . PubMed
  182. Sivapatham S, et al. 2019. Front Immunol. 1.865277778. PubMed
  183. Zhao Y, et al. 2020. Front Immunol. 2.572222222. PubMed
  184. Sun F, et al. 2022. Cell Death Dis. 13:181. PubMed
  185. Zhong C, et al. 2021. J Virol. 95:e0092521. PubMed
  186. Magee JA, et al. 2021. Stem Cell Reports. 16:20. PubMed
  187. Xu Y, et al. 2021. iScience. 24:103445. PubMed
  188. Zhou S, et al. 2021. Adv Funct Mater. 31:. PubMed
  189. Smith KJ, et al. 2022. PLoS Biol. 20:e3001554. PubMed
  190. Sears SM, et al. 2022. Kidney360. 3:818. PubMed
  191. Bryan Hart, Sunhee Lee 2016. PLoS Negl Trop Dis. 10:e0005229. PubMed
  192. Blaszczak AM, et al. 2020. Immunometabolism. 2:00. PubMed
  193. Yang C, et al. 2020. Cell Host Microbe. 467:27. PubMed
  194. Ramanan D, et al. 2020. Cell. 181(6):1276-1290. PubMed
  195. Hidalgo San Jose L, et al. 2020. Cell Rep. 30:69. PubMed
  196. Blaszczak AM, et al. 2019. J Immunol. 202:2451. PubMed
  197. Liang Z, et al. 2017. Autophagy. 14:505. PubMed
  198. Nakao R, et al. 2022. NPJ Vaccines. 7:153. PubMed
  199. Wang Y, et al. 2022. Nat Commun. 13:1454. PubMed
  200. Barsoumian HB, et al. 2022. Cancers (Basel). 14:. PubMed
  201. Chen YL, et al. 2022. Front Neurosci. 16:876582. PubMed
  202. Li Z, et al. 2022. Evid Based Complement Alternat Med. 2022:7421265. PubMed
  203. Yue T, et al. 2022. Cell Death Differ. 29:218. PubMed
  204. Aguilera TA, et al. 2020. Clin Cancer Res. 26:2972. PubMed
  205. Simoni L, et al. 2020. Cell Rep. 33:108330. PubMed
  206. Hart B, et al. 2015. PLoS Negl Trop Dis. 9: 0004046. PubMed
  207. Bartley A, et al. 2018. Front Physiol. 9:1593. PubMed
  208. Timilshina M, et al. 2020. Cell Reports. 27(10):2948-2961.e7.. PubMed
  209. Hong Y, et al. 2019. J Extracell Vesicles. 8:1670893. PubMed
  210. Hsu HP, et al. 2021. J Biol Chem. 296:100419. PubMed
  211. Zhang M, et al. 2022. iScience. 25:104490. PubMed
  212. Chen Y, et al. 2021. Braz J Med Biol Res. 54:e9570. PubMed
  213. Rodrigues KA, et al. 2021. Sci Adv. 7:eabj6538. PubMed
  214. Kathania M, et al. 2022. Cell Rep. 40:111345. PubMed
  215. Gawish R, et al. 2022. Elife. 11:. PubMed
  216. Li J, et al. 2022. Nat Commun. 13:1481. PubMed
  217. Angela M, et al. 2016. Nat Commun. 7:13683. PubMed
  218. Gardenier J, et al. 2017. Nat Commun. 8:14345. PubMed
  219. Jaeger N, et al. 2020. Cell Rep. 33:108331. PubMed
  220. Zeng A, et al. 2020. Oncol Rep. . PubMed
  221. Zhou T, et al. 2018. Mol Med Rep. 17:4883. PubMed
  222. Li CY, et al. 2022. Int J Mol Sci. 23:. PubMed
  223. Liang Z, et al. 2022. iScience. 25:105233. PubMed
  224. Lestari SR, et al. 2020. J Ayurveda Integr Med. 11:414. PubMed
  225. Jiang W, et al. 2021. Cell Rep. 37:110112. PubMed
  226. Chang MH, et al. 2021. Cell Rep. 37:109902. PubMed
  227. Ding X, et al. 2021. Front Immunol. 12:667136. PubMed
  228. Guo S, et al. 2021. Frontiers in Immunology. 11:614667. PubMed
  229. Cortez MA, et al. 2020. Nat Commun. 3.819444444. PubMed
RRID
AB_312690 (BioLegend Cat. No. 100405)
AB_312691 (BioLegend Cat. No. 100406)

Antigen Details

Structure
Ig superfamily, 55 kD
Distribution

Majority of thymocytes, T cell subset

Function
TCR co-receptor, T cell activation
Ligand/Receptor
MHC class II molecule
Cell Type
Dendritic cells, T cells, Thymocytes, Tregs
Biology Area
Immunology
Molecular Family
CD Molecules
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Bierer BE, et al. 1989. Annu. Rev. Immunol. 7:579.
3. Janeway CA. 1992. Annu. Rev. Immunol. 10:645.

Gene ID
12504 View all products for this Gene ID
UniProt
View information about CD4 on UniProt.org

Related FAQs

I am unable to see expression of T cell markers such as CD3 and CD4 post activation.
TCR-CD3 complexes on the T-lymphocyte surface are rapidly downregulated upon activation with peptide-MHC complex, superantigen or cross-linking with anti-TCR or anti-CD3 antibodies. PMA/Ionomycin treatment has been shown to downregulate surface CD4 expression. Receptor downregulation is a common biological phenomenon and so make sure that your stimulation treatment is not causing it in your sample type.

Other Formats

View All CD4 Reagents Request Custom Conjugation
Description Clone Applications
APC anti-mouse CD4 GK1.5 FC
Biotin anti-mouse CD4 GK1.5 FC,IHC-F,ICC
FITC anti-mouse CD4 GK1.5 FC,IHC-F,ICC
PE anti-mouse CD4 GK1.5 FC
PE/Cyanine5 anti-mouse CD4 GK1.5 FC
Purified anti-mouse CD4 GK1.5 FC,IHC-F,ICC,IP,Costim,Block,Depletion
PE/Cyanine7 anti-mouse CD4 GK1.5 FC
APC/Cyanine7 anti-mouse CD4 GK1.5 FC
Alexa Fluor® 647 anti-mouse CD4 GK1.5 FC,IHC-F,ICC
Alexa Fluor® 488 anti-mouse CD4 GK1.5 FC,IHC-F,ICC
Pacific Blue™ anti-mouse CD4 GK1.5 FC
Alexa Fluor® 700 anti-mouse CD4 GK1.5 FC
PerCP anti-mouse CD4 GK1.5 FC
PerCP/Cyanine5.5 anti-mouse CD4 GK1.5 FC
Brilliant Violet 421™ anti-mouse CD4 GK1.5 FC,ICC,IHC-F
Ultra-LEAF™ Purified anti-mouse CD4 GK1.5 FC,Block,Costim,Depletion,IHC,IP
Alexa Fluor® 594 anti-mouse CD4 GK1.5 IHC-F,FC,ICC,SB
Brilliant Violet 711™ anti-mouse CD4 GK1.5 FC
Brilliant Violet 510™ anti-mouse CD4 GK1.5 FC,IHC-F,ICC
Brilliant Violet 605™ anti-mouse CD4 GK1.5 FC
Brilliant Violet 785™ anti-mouse CD4 GK1.5 FC
PE/Dazzle™ 594 anti-mouse CD4 GK1.5 FC
APC/Fire™ 750 anti-mouse CD4 GK1.5 FC
GoInVivo™ Purified anti-mouse CD4 GK1.5 FC
Brilliant Violet 750™ anti-mouse CD4 GK1.5 FC
Brilliant Violet 650™ anti-mouse CD4 GK1.5 FC
Spark Blue™ 550 anti-mouse CD4 GK1.5 FC
Spark NIR™ 685 anti-mouse CD4 GK1.5 FC
KIRAVIA Blue 520™ anti-mouse CD4 GK1.5 FC
PE/Fire™ 640 anti-mouse CD4 GK1.5 FC
APC/Fire™ 810 anti-mouse CD4 GK1.5 FC
PE/Fire™ 700 anti-mouse CD4 GK1.5 FC
Spark Violet™ 538 anti-mouse CD4 GK1.5 FC
Spark YG™ 593 anti-mouse CD4 GK1.5 FC
Spark Blue™ 574 anti-mouse CD4 Antibody GK1.5 FC
Spark UV™ 387 anti-mouse CD4 GK1.5 FC
Go To Top Version: 1    Revision Date: 11/30/2012

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

 

*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/ordering#license). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

  • APC anti-mouse CD4

  • Biotin anti-mouse CD4

  • FITC anti-mouse CD4

  • PE anti-mouse CD4

  • PE/Cyanine5 anti-mouse CD4

  • Purified anti-mouse CD4

  • PE/Cyanine7 anti-mouse CD4

  • APC/Cyanine7 anti-mouse CD4

  • Alexa Fluor® 647 anti-mouse CD4

  • Alexa Fluor® 488 anti-mouse CD4

  • Pacific Blue™ anti-mouse CD4

  • Alexa Fluor® 700 anti-mouse CD4

  • PerCP anti-mouse CD4

  • PerCP/Cyanine5.5 anti-mouse CD4

  • Brilliant Violet 421™ anti-mouse CD4

  • Ultra-LEAF™ Purified anti-mouse CD4

  • Alexa Fluor® 594 anti-mouse CD4

  • Brilliant Violet 711™ anti-mouse CD4

  • Brilliant Violet 510™ anti-mouse CD4

  • Brilliant Violet 605™ anti-mouse CD4

  • Brilliant Violet 785™ anti-mouse CD4

  • PE/Dazzle™ 594 anti-mouse CD4

  • APC/Fire™ 750 anti-mouse CD4

  • GoInVivo™ Purified anti-mouse CD4

  • Brilliant Violet 750™ anti-mouse CD4

  • Brilliant Violet 650™ anti-mouse CD4

  • Spark Blue™ 550 anti-mouse CD4

  • Spark NIR™ 685 anti-mouse CD4

  • KIRAVIA Blue 520™ anti-mouse CD4

  • PE/Fire™ 640 anti-mouse CD4

  • APC/Fire™ 810 anti-mouse CD4

  • PE/Fire™ 700 anti-mouse CD4

  • Spark Violet™ 538 anti-mouse CD4

  • Spark YG™ 593 anti-mouse CD4

  • Spark Blue™ 574 anti-mouse CD4 Antibody

  • Spark UV™ 387 anti-mouse CD4
ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account